Home » Stocks » Genfit

Genfit S.A. (GNFT)

Stock Price: $4.50 USD 0.07 (1.58%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 174.65M
Revenue (ttm) 46.02M
Net Income (ttm) -65.14M
Shares Out 38.81M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $4.50
Previous Close $4.43
Change ($) 0.07
Change (%) 1.58%
Day's Open 4.52
Day's Range 4.44 - 4.54
Day's Volume 2,581
52-Week Range 3.65 - 22.48

More Stats

Market Cap 174.65M
Enterprise Value 70.01M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.81M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.98
FCF / Share -1.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 77,720
Short Ratio 0.68
Short % of Float n/a
Beta 0.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.79
PB Ratio 4.67
Revenue 46.02M
Operating Income -64.98M
Net Income -65.14M
Free Cash Flow -53.03M
Net Cash 104.64M
Net Cash / Share 2.70
Gross Margin 100.00%
Operating Margin -141.19%
Profit Margin -159.00%
FCF Margin -115.21%
ROA -13.70%
ROE -105.20%
ROIC -32.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 3
Overweight 0
Hold 4
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(140.89% upside)
Current: $4.50
Target: 10.84
*Average 12-month USD price target from 8 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth446.58%9.31%-
Gross Profit40.967.496.86
Operating Income-57.83-69.49-56.69
Net Income-65.14-79.52-55.73
Shares Outstanding36.1836.18-
Earnings Per Share-1.76-2.55-1.79
Operating Cash Flow-47.68-56.08-49.86
Capital Expenditures0.49-2.94-2.79
Free Cash Flow-47.19-59.02-52.64
Cash & Equivalents277207274
Total Debt184170165
Net Cash / Debt93.1337.65109
Book Value84.0720.94101
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Genfit S.A.
Country France
Employees 174
CEO Pascal Prigent

Stock Information

Ticker Symbol GNFT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GNFT
IPO Date March 27, 2019


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.